



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Manuel A. Franco  
✉ mafranco@javeriana.edu.co

RECEIVED 08 August 2023

ACCEPTED 09 August 2023

PUBLISHED 16 August 2023

## CITATION

Martel F, Cuervo-Rojas J, Ángel J, Ariza B, González JM, Ramírez-Santana C, Acosta-Ampudia Y, Murcia-Soriano L, Montoya N, Cardozo-Romero CC, Valderrama-Beltrán SL, Cepeda M, Castellanos JC, Gómez-Restrepo C, Perdomo-Celis F, Gazquez A, Dickson A, Brien JD, Mateus J, Grifoni A, Sette A, Weiskopf D and Franco MA (2023) Corrigendum: Cross-reactive humoral and CD4<sup>+</sup> T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population. *Front. Immunol.* 14:1274753. doi: 10.3389/fimmu.2023.1274753

## COPYRIGHT

© 2023 Martel, Cuervo-Rojas, Ángel, Ariza, González, Ramírez-Santana, Acosta-Ampudia, Murcia-Soriano, Montoya, Cardozo-Romero, Valderrama-Beltrán, Cepeda, Castellanos, Gómez-Restrepo, Perdomo-Celis, Gazquez, Dickson, Brien, Mateus, Grifoni, Sette, Weiskopf and Franco. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Corrigendum: Cross-reactive humoral and CD4<sup>+</sup> T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population

Fabiola Martel<sup>1</sup>, Juliana Cuervo-Rojas<sup>2</sup>, Juana Ángel<sup>1</sup>, Beatriz Ariza<sup>3</sup>, John Mario González<sup>4</sup>, Carolina Ramírez-Santana<sup>5</sup>, Yeny Acosta-Ampudia<sup>5</sup>, Luisa Murcia-Soriano<sup>6</sup>, Norma Montoya<sup>7</sup>, Claudia Cecilia Cardozo-Romero<sup>3</sup>, Sandra Liliana Valderrama-Beltrán<sup>8</sup>, Magda Cepeda<sup>2</sup>, Julio César Castellanos<sup>9</sup>, Carlos Gómez-Restrepo<sup>2</sup>, Federico Perdomo-Celis<sup>1</sup>, Andreu Gazquez<sup>10</sup>, Alexandria Dickson<sup>10</sup>, James D. Brien<sup>10</sup>, José Mateus<sup>11</sup>, Alba Grifoni<sup>11</sup>, Alessandro Sette<sup>11,12</sup>, Daniela Weiskopf<sup>11</sup> and Manuel A. Franco<sup>1\*</sup>

<sup>1</sup>Institute of Human Genetics, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia,

<sup>2</sup>Department of Clinical Epidemiology and Biostatistics, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia, <sup>3</sup>Clinical Laboratory Science Research Group, Clinical Laboratory, Hospital Universitario San Ignacio, Bogotá, Colombia, <sup>4</sup>Group of Basic Medical Sciences, School of Medicine, Universidad de Los Andes, Bogotá, Colombia, <sup>5</sup>Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia, <sup>6</sup>Hospital Universitario Mayor-Méridi, Universidad El Rosario, Bogotá, Colombia, <sup>7</sup>Head Clinical Laboratory Unit, Clínica del Occidente, Bogotá, Colombia, <sup>8</sup>Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Pontificia Universidad Javeriana, Hospital Universitario San Ignacio Infectious Diseases Research Group, Bogotá, Colombia, <sup>9</sup>General Direction, Hospital Universitario San Ignacio, Bogotá, Colombia, <sup>10</sup>Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, MO, United States, <sup>11</sup>Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, United States, <sup>12</sup>Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA, United States

## KEYWORDS

SARS-CoV-2, variants, natural infection, vaccination, antibody, CD4<sup>+</sup> T cell, hybrid immunity, breakthrough infections

## A Corrigendum on

**Cross-reactive humoral and CD4<sup>+</sup> T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population**

by Martel F, Cuervo-Rojas J, Ángel J, Ariza B, González JM, Ramírez-Santana C, Acosta-Ampudia Y, Murcia-Soriano L, Montoya N, Cardozo-Romero CC, Valderrama-Beltrán SL, Cepeda M, Castellanos JC, Gómez-Restrepo C, Perdomo-Celis F, Gazquez A, Dickson A, Brien JD, Mateus J, Grifoni A, Sette A, Weiskopf D and Franco MA (2023). *Front. Immunol.* 14:1241038. doi: 10.3389/fimmu.2023.1241038

In the published article, there was an error in affiliation 5. Instead of “Center for the Study of Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota’, Colombia”, it should be “Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.